NEWS

Jury Still Out on Omega-3s for Depression

November 10, 2015

By Kathryn Doyle

NEW YORK - There is not enough evidence to support over-the-counter omega-3 fatty acid supplements as a treatment for depression, according to a new review.

"A number of other reviews investigating the impact of omega-3 fatty acids on depression and depressive disorders have also been conducted, and all of these also find discrepancies between studies, and inconsistencies in findings, and essentially find it difficult to draw convincing conclusions," lead author Dr. Katherine Appleton of the University of Bournemouth in the UK, told Reuters Health by email.

"All reviews also conclude with the need for further evidence," she said.

The new review included 26 randomized controlled trials involving almost 1,500 adults with major depressive disorder. The trials compared people who were given omega-3 fatty acid capsules and people given placebo pills.

Only one study compared omega-3 capsules to an antidepressant medication.

While people who took the omega-3 capsules did report lower levels of depression symptoms compared to the placebo group, there was only a small difference that would likely not be meaningful for most people, the authors write in an article online November 5 in the Cochrane Library.

Side effects and adverse events may have increased for some people taking omega-3 capsules, but the results varied widely from study to study. The quality of evidence from each study was low to very low, in the authors' rating.

In the one study including antidepressants, researchers found no difference between omega-3 fatty acid supplements and antidepressants for depressive symptoms.

The results are "promising, but not conclusive," Dr. Giuseppe Grosso, a nutritional epidemiologist at the University of Catania in Italy, who was not part of the review, told Reuters Health by email.

It's not clear why, or how, the omega-3 fatty acids naturally found in fish oil would improve depressive symptoms, although inflammation and cell communication changes, among other pathways, have been suggested, Dr. Appleton said.

"One of the problems with understanding results from clinical trials in general is that they are looking for an average effect, while many experts agree that the ideal approach would be to figure out which subsets of depressed patients could benefit from particular treatments," Dr. Elizabeth Sublette of Columbia University in New York, who was not part of the new review, told Reuters Health by email.

"At this stage we don't yet know how to predict which depressed patients will respond to omega-3 supplements," Dr. Sublette said. "They remain one potential treatment that may be worth trying, and I would encourage both doctors and patients to keep an open mind about this topic until more evidence of higher quality can be obtained."

Most omega-3 supplements are composed of natural oils, so there is no evidence to suggest the results of the trials would have been different if the omega-3 acids came from eating fish rather than taking capsules, she said.

More research is needed to assess the potential positive and negative effects of using these supplements to treat major depressive disorder, Dr. Appleton and her colleagues write.

"Many possible treatments for depression are currently being investigated, but the evidence for many of these treatments is still incomplete," she said.

Funding and disclosures varied by study reviewed.

SOURCE: http://bit.ly/1HFLp0f

Cochrane Database Syst Rev 2015.

 

(c) Copyright Thomson Reuters 2015. Click For Restrictions - http://about.reuters.com/fulllegal.asp